DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,243,776 shares of the medical device company's stock after purchasing an additional 100,300 shares during the quarter. Two Sigma Advisers LP owned about 0.32% of DexCom worth $96,728,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of DXCM. Private Trust Co. NA increased its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new position in DexCom during the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC increased its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in DexCom during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This trade represents a 10.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 over the last ninety days. Corporate insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Citigroup upped their price target on shares of DexCom from $82.00 to $102.00 and gave the company a "buy" rating in a research note on Thursday. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Piper Sandler cut their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $98.00.

DexCom Price Performance

DXCM traded down $0.06 during trading on Thursday, hitting $84.83. The company's stock had a trading volume of 1,693,852 shares, compared to its average volume of 4,361,280. The firm has a market capitalization of $33.26 billion, a price-to-earnings ratio of 59.32, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $129.97. The business's fifty day simple moving average is $72.99 and its 200 day simple moving average is $77.92. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business earned $0.32 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.